Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| 4MaBV | 4MaBV55 | U.S. | 1994 | HIV1 | B | Plasma | MMC |
Treatment History
| Order | Regimen | Weeks |
| 1 | NRTI+IDV | 55 |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| M46L, I54V, V82A | L63P, A71V |
| >4MaBV55| 49 | codons 1-99 | clone 49 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKLIGGIGGFVKVRQYD QIPIEICGHKVIGTVLVGPTPANIIGRNLLTQIGCTLNF >4MaBV55| 50 | codons 1-99 | clone 50 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKLIGGIGGFVKVRQYD QIPIEICGHKAIGTVLVGPTPANIIGRNLLTQIGCTLNF >4MaBV55| 51 | codons 1-99 | clone 51 PQITLWQRPLVTIKIGGQLKEALLDTGADDTILEEMNLPGRWKPKLIGGIGGFIKVRQYD QIPIEICGHKVIGTVLVGPTPANIIGRNLLTQIGCTLNF >4MaBV55| 54 | codons 1-99 | clone 54 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKLIGGIGGFVKVRQYD QIPIEICGHKAIGTVLVGPTPANIIGRNLLTQIGCTLNF >4MaBV55| 56 | codons 1-99 | clone 56 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKLIGGIGGFVKVRQYD QIPIEICGHKAIGTVLVGPTPANIIGRNLLTQIGCTLNF >4MaBV55| 57 | codons 1-99 | clone 57 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKLIGGIGGFVKVRQYD QIPIEICGHKVIGTVLVGPTPANIIGRNLLTQIGCTLNF >4MaBV55| 83 | codons 1-99 | clone 83 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKLIGGIGGFVKVRQYD QIPIEICGHKVIGTVLVGPTPANIIGRNLLTQIGCTLNF >4MaBV55| 85 | codons 1-99 | clone 85 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKLIGGIGGFVKVRQYD QIPIEICGHKAIGTVLVGPTPANIIGRNLLTQIGCTLNF >4MaBV55| codons 1-99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKLIGGIGGFVKVRQYD QIPIEICGHKVIGTVLVGPTPANIIGRNLLTQIGCTLNF |
References
| Author | Title | Citation |
| Zhang, Y-M | Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its gag substrate cleavage sites. | J Virol, 1997 |
| Rhee, SY | HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance. | J Infect Dis, 2005 |